Background
The number of patients receiving anticoagulants is increasing year by year and this currently involves millions of people worldwide. Therefore, it is not surprising that many of these patients need invasive or surgical procedures. In fact, it has been estimated that around one in 10 patients taking anticoagulants for cardioembolic prevention in non-valvular atrial fibrillation and mechanical heart diseases or prevention of venous thromboembolism recurrence, require surgery each year. 1 In the RE-LY study, approximately 25% of patients assigned to both doses of dabigatran and warfarin needed invasive surgical procedures. 2 The peri-procedural period represents a condition at high bleeding risk, requiring discontinuation of anticoagulants but this period is in any case at high risk of embolic complications due to discontinuation of antithrombotic drugs. 3 The balance between bleeding and embolic risk is of the utmost importance for driving the optimal management of anticoagulation in the peri-operative setting. Anticoagulants should be stopped in high bleeding risk procedures; this means 2-4% of major bleeds rate within 48 h of surgery, while low bleeding risk procedures (0-2% within 48 h) also represent a cause for concern (Table 1) . 4 When interruption of therapy is indicated, the practical recommendations for vitamin K antagonists in the peri-operative setting suggest their discontinuation five days before surgery and their resumption 24-48 h after surgery if adequate hemostasis has been achieved. 3 Together with the bleeding risk secondary to procedures, the individual bleeding risk should also be assessed (Table 2) . 5 On the other hand, the individual and procedural embolic risk should be closely evaluated. Within the thromboembolic diseases represented by mechanical valve diseases, atrial fibrillation and venous thromboembolism, it is possible to stratify patients in high-, moderate-and low-risk patients for embolic complications after drug discontinuation (Table 3) . 3 For highrisk patients in whom the embolic risk overcomes the bleeding risk, the bridging therapy with low molecular weight heparins (LMWH) in anticoagulant doses is strongly recommended.
3 LMWH at anticoagulant dosage should be started five days before procedure, discontinued 24 h before from surgery and resumed 12-24 h after the procedure. 3 However, a recently published metaanalysis seems to demonstrate that the bridging therapy is associated with higher bleeding risk without advantages in reducing the embolic risk. 
ABSTRACT
When a patient receiving new oral anticoagulants (NOACs) requires an invasive procedure, the consequences of bleeding if anticoagulation is continued and the risk of thrombosis if it is omitted need to be carefully considered. In addition to the bleeding risk of the procedure, it is of paramount importance to evaluate the renal function, especially for dabigatran that is eliminated predominantly via the renal pathway. NOAC therapy should be stopped for at least 24 h before the intervention, and a longer interruption should be considered in cases of high bleeding risk procedures and/or renal failure. A base-line assessment of coagulation should be performed and intervention should be postponed (if possible) if high levels of anticoagulation parameters are found. In the post-surgical period, if oral anticoagulant therapy cannot be re-started, patients should temporarily receive low molecular weight heparins and re-start NOACs as soon as possible. How to manage new oral anticoagulants (NOACs) and surgery. In the RE-LY study, the bleeding risk in the peri-procedural period was similar between both doses of dabigatran (110 mg/bid and 150 mg/bid) and warfarin, but the median time of drug discontinuation before the invasive procedures was significantly shorter in dabigatran patients (median 2 days) compared to the group treated with warfarin (median 5 days).
2
Despite this lack of evidence, practical recommendations for management of NOACs in the peri-procedural setting have been indicated. [7] [8] [9] [10] In patients treated with NOACs and requiring invasive procedures, it is first necessary to clearly identify the level of urgency of the intervention (election, urgency, emergency) and subsequently to consider the following issues:
-the thrombotic and hemorrhagic risk of the procedure and of the patient; -the NOAC half-life [which is shorter than vitamin K antagonists (VKAs)] in patients with normal and impaired renal function; -the onset of anticoagulation effect of NOACs (which is usually within 2 h provided that intestinal absorption is normal); -the dose and the timing of the last intake of the drug; -the possibility of pharmacological reversal of anticoagulation in case of emergency procedures.
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Elective surgery
If patients require an invasive procedure or surgical intervention, NOAC therapy should be discontinued (ide- Table 1 . Procedural bleeding risk.
High risk (48-h bleeding rate 2-4%)
• Heart valve replacement Table 2 . Individual bleeding risk.
• Active bleeding Review ally for at least 24 h before the intervention) and restarted when adequate hemostasis has been re-established. This applies to patients who are scheduled to undergo surgery. However, if emergency surgery is needed, no further NOAC tablets should be taken and, if possible, surgery should be delayed until the half-life of the NOACs has elapsed. In this scenario, the prothrombin time test with the use of a rivaroxaban-sensitive reagent (such as Néoplastine CI Plus) (for rivaroxaban) or a chromogenic anti-Factor Xa assay (for rivaroxaban and apixaban) or an activated partial thromboplastin partial time/diluted thrombin time (dTT, Hemoclot) assay (for dabigatran) should be used to measure anticoagulant activity in plasma. Persistently high levels of anticoagulation parameters are suggestive of high plasmatic levels of NOACs and the intervention, if possible, should be postponed. If the procedure cannot be delayed, the treating physician should assess the increased risk of bleeding against the urgency of the intervention. After the intervention, NOACs should be re-started as soon as possible (however, at least 12 h after the end of the procedure), provided that the clinical situation allows, and that adequate hemostasis has been established; moreover, according to the thrombotic and bleeding risk and to the type of procedure, re-starting with a lower dose of NOACs is advisable (for example 10 mg/day for rivaroxaban, half a daily dose for dabigatran and apixaban). It is worthy of note that, owing to the fast onset of action of NOACs, it is not necessary for patients to receive bridging therapy with parenteral unfractionated heparin or LMWH after the procedure. When oral treatment cannot be administered immediately after surgery, patients should re-start anticoagulant therapy with LMWH and re-introduce NOACs as soon as possible.
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Emergency procedures/surgery
In emergency surgery for non-bleeding patient, every attempt should be made to delay surgery, at least for 24 h. If the intervention or the procedure (e.g. emergency coronary angioplasty, or a diagnostic endoscopic procedure) is at low bleeding risk, NOAC administration should be continued. If bleeding risk is increased it is recommended to assess the presence and entity of anticoagulant activity by the abovementioned laboratory tests. If residual anticoagulant activity is detected, the use of non-activated prothrombin complex concentrates (PCCs) or activated PCCs (FEIBA) should be considered for the urgent reversal of patients treated with dabigatran and PCCs for rivaroxaban 4 when the procedure cannot be postponed and the risk of bleeding is very high. When surgery cannot be delayed, or in patients requiring surgical approach to stop bleeding, the urgent reversal of NOACs should be performed.
7-10
The peri-operative management of patients treated with NOACs is summarized in Table 4 .
How to manage anesthesia in patients receiving NOACs
In the surgical setting, the optimal management of antithrombotic drugs according to the kind of anesthesia is fundamental. While there are no particular recommendations for general anesthesia other than those abovementioned for DOACs withdrawal, neuraxial anesthesia requires close attention in patients taking antithrombotic drugs due to bleeding risk in the phases of insertion and removal of epidural catheter. 13 Epidural catheter can be inserted or removed only after a period of time corresponding to the sum of two half-lives plus the time needed to reach the plasma peak concentration. Moreover, after catheter insertion or removal, the antithrombotic drug can be administered after a time corresponding to the clot formation which is around 8 h less the time to reach the peak plasma concentration (Table 5) . 13, 14 
How to manage new oral anticoagulants
How to switch from NOACs to other anticoagulants and vice versa
Both in the surgical setting and in other situations, the switch between VKAs or LMWHs or unfractionated heparin and NOACs or vice versa could be necessary. The practical recommendations for the switching between VKAs and NOACs suggest to start dabigatran when the international normalized ratio (INR) values are less than 2.0 and rivaroxaban when INR are less than 3.0, and conversely, the VKAs should be started from three days before to the day before the NOACs withdrawal based on CrCl. 7, 8 In patients with normal CrCl, VKAs can be assumed from three days between discontinuation of DAOC, while patients with moderate renal impairment, VKAs should be assumed the day before the NOACS withdrawal. 7, 8 The NOACs may be administered at the appointed time of LMWHs and vice versa LMWHs can be administered at the appointed time of NOACs when it is decided to switch from one to another therapy. 7, 8, 15 The NOACs may be administered 2 h after discontinuation of intravenous unfractionated heparin and intravenous unfractionated heparin can be started at the time of the planned dose of the NOACs. 7, 8, 15 
Conclusions
In conclusion, peri-operative management of NOACs seems to be simpler and easier than of warfarin for several reasons, i.e. shorter half-life, faster offset and onset of action, no need for bridging therapy with LMWHs. Of course, these considerations should be confirmed in large scale, well-designed clinical trials. 
